FCMI
IMMU

Foresite Capital Management III’s Immunomedics Inc IMMU Stock Holding History

Foresite Capital Management III’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-150,000
Closed -$3.55M – 26
2018
Q2 		$3.55M Buy
+150,000
New +$3.01M 0.76% 20

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Foresite Capital Management III's IMMU Position: Q2 2020 in Review

Foresite Capital Management III sold out of Immunomedics Inc (IMMU) in Q2 2020, closing a stake of 400,000 shares — an estimated $5.39M sold.

Foresite Capital Management III first reported a position in IMMU in Q1 2017 and held it in 13 quarters. The position peaked at $60.2M in Q2 2018. 313 funds tracked by Wall St. Rank hold IMMU as of Q2 2020.

  • Foresite Capital Management III reported no remaining Immunomedics Inc position as of Q2 2020 after selling out during the quarter.
  • Foresite Capital Management III sold 400,000 Immunomedics Inc shares in Q2 2020, an estimated $5.39M.
  • Foresite Capital Management III first reported a position in Immunomedics Inc in Q1 2017 and held it in 13 quarters.
  • Foresite Capital Management III's Immunomedics Inc position peaked at $60.2M in Q2 2018.
  • 313 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2020.

Based on Foresite Capital Management III's 13F filing for Q2 2020, filed 13 Aug 2020.